SLN · Silence Therapeutics Plc

The thesis

Silence Therapeutics' divesiran data are still positive, but the market has not rewarded them. The shares closed at $9.86 on 9 October 2026, below the $13.50 price of the August offering, and the next quarterly report and the first-half 2027 Phase 3 start settle whether the case recovers.

The earlier threshold failed. The prior note set a weekly close below $11.18 (the 25 September 2026 adjusted close) as the break of the recovery case. The 9 October 2026 close of $9.86 is below that level. The post-readout narrative is dead as a price story: the stock is 36.1% under its $15.43 52-week high, and the 10 August 2026 clinical result has the shares up. The clinical asset itself is intact on the evidence published so far.

Bullish and bearish views on Silence Therapeutics Plc

The bull case on Silence Therapeutics Plc (SLN), in brief: Divesiran met its trial endpoint. The bear case: The shares trade below the offering price.

Bull case

• Divesiran met its trial endpoint. Silence reported on 10 August 2026 that 88% of divesiran-treated patients responded versus 19% on placebo in the 48-patient Phase 2 SANRECO trial. The every-12-week dosing group had an 81.3% response rate. Company topline release
• A Phase 3 start is guided. The company guided on 10 August 2026 to start a divesiran Phase 3 trial in polycythemia vera in the first half of 2027. Until then it is the only company-dated clinical milestone.
• Fresh capital was raised. Silence priced 12,962,963 ADSs at $13.50 on 12 August 2026 for about $175 million gross, and the offering closed on 14 August 2026. The Q3 report is the first chance to see the resulting cash balance.
• The selling looks extreme. The 14-day relative strength index, a 0-to-100 momentum gauge, was 15.4 on 9 October 2026 and 8.9 on 25 September 2026. Both readings are deeply oversold. That describes the speed of the decline, not a turn.

Bear case

• The shares trade below the offering price. The adjusted close of $9.86 on 9 October 2026 is under the $13.50 paid by investors in the August offering. Those buyers hold a loss, and the $175 million raise added 12,962,963 shares to the market.
• The prior support level failed. The close fell from $11.18 on 25 September 2026 to $9.86 on 9 October 2026. The three-month price change of 1.1% shows the readout gain is gone.
• The second program lacks a partner. Silence's 10 August 2026 business update described zerlasiran as Phase 3-ready but dependent on a third-party development commitment. Novartis reported on 4 September 2026 that its Lp(a)-lowering drug pelacarsen missed its primary cardiovascular-events endpoint in a Phase 3 trial. Pelacarsen targets the same lipoprotein(a) pathway as zerlasiran, which makes a partner for zerlasiran harder to find. Second-quarter results
• Full results are undated. The 10 August 2026 release promised full SANRECO results at a future medical congress without a date. A 48-patient study leaves longer-term efficacy and safety open.

Price setup

The adjusted close on 9 October 2026 was $9.86, 36.1% below the $15.43 52-week high. The 14-day relative strength index was 15.4. The stock is also well under the $13.50 offering price, which is the nearest reference level overhead; a weekly close back above it would be the first sign that the post-readout decline had reversed.

The narrative stage is a failed rally, not crowding at a peak. No SEC Form 4 insider filings or other company filings appeared in news coverage for the period since 27 September 2026. Shares issued at $13.50 into the August strength are the clearest sign of supply into a rally. The next earnings date is about 9 November 2026 (estimated), at the edge of the 30-day window. Sell-side targets quoted in secondary coverage range widely and the ones found were not dated within the last 14 days, so none is relied on here.

Catalysts, next 30 days

• Nothing company-dated is confirmed through ~9 November 2026. The September conference appearances (Cantor on 9 September 2026, H.C. Wainwright on 15 September 2026, Morgan Stanley on 16 September 2026) have passed.
• ~9 November 2026 (est.): Third-quarter 2026 results. They give the first cash figure after the $175 million raise and an update on zerlasiran partnering.
• Undated: Full SANRECO data at a medical congress.
• ~1H 2027 (est.): Divesiran Phase 3 initiation.

What would change the view

The case breaks on a daily close below $8.50, a round level under the 9 October 2026 close that would extend the slide from the $15.43 high. It also breaks if the company moves the divesiran Phase 3 start beyond the first half of 2027, or if the Q3 report shows no zerlasiran partner and a cash runway that falls short of the Phase 3 plan.

The case improves on a weekly close above $13.50, the August offering price, or on a signed zerlasiran development agreement. Neither has happened as of 9 October 2026. This note stays at low conviction because the price evidence points down and the next company-dated event falls at the end of the window.

What it trades with

Silence trades with small and mid-cap biotech, where its beta of 1.72 (a figure from secondary quote sites, not a company filing) means larger moves than the market. The Lp(a) group is the closest peer set: Novartis's pelacarsen miss on 4 September 2026 reached zerlasiran's investment case directly. The divesiran case depends mostly on its own polycythemia vera data and Phase 3 timing.